<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866290</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-P4-16-01</org_study_id>
    <nct_id>NCT04866290</nct_id>
  </id_info>
  <brief_title>HepaSphere™ Microspheres Prospective Registry</brief_title>
  <acronym>mCRC</acronym>
  <official_title>Prospective Registry of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver With HepaSphere™ Microspheres Loaded With Irinotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HepaSphere Microspheres loaded with irinotecan received CE mark for the indication of use in&#xD;
      embolization of mCRC to the liver in 2015. The goal of this registry is to add to the&#xD;
      understanding of the use and value of transarterial chemoembolization with HepaSphere in&#xD;
      'real life' usage conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2016</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Median overall survival of subjects treated with HepaSphere Microspheres loaded with irinotecan. Analysis will be performed when all subjects enrolled have been followed for survival for two years (24 months), are considered lost to follow up, or have died, whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Response Rate (ORR) as determined by mRECIST criteria will be calculated when all subjects enrolled have been followed for survival for two years (24 months from the date of their first TACE), are considered lost to follow up, or have died, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>24 months</time_frame>
    <description>Best Tumor Response (during the period of time between the first TACE and the last post TACE MRI or CT) as determined by mRECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Median liver progression-free survival will be calculated as the time (in months) between the first TACE procedure to the date on which progression of the subject's liver metastases was documented or the date of death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>24 months</time_frame>
    <description>Time to Progression, including extrahepatic progression, utilizing the date of the first study TACE as time zero</description>
  </secondary_outcome>
  <enrollment type="Actual">105</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HepaSphere Microspheres</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with metastatic colorectal cancer with metastases to the liver&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or radiologically confirmed colorectal cancer metastases to the liver&#xD;
&#xD;
          -  Patient is able to have either CT or MRI imaging&#xD;
&#xD;
          -  Hepatic tumor burden ≥50% of total tumor burden&#xD;
&#xD;
          -  Hepatic tumor burden ≤50% of total liver volume&#xD;
&#xD;
          -  Not suitable for treatment by resection or percutaneous ablation at time of TACE&#xD;
             treatment&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  WHO performance status ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with any form of hepatic transarterial embolization&#xD;
&#xD;
          -  Total bilirubin ≥ 3.0 mg/dL&#xD;
&#xD;
          -  Any contraindication for irinotecan administration&#xD;
&#xD;
          -  Partial or complete thrombosis of the main portal vein&#xD;
&#xD;
          -  Cardiovascular or respiratory failure&#xD;
&#xD;
          -  Any other condition deemed exclusionary by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katerina Malagari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evgenidio Hospital/ATTIKO Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Hospital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evgenidio Hospital/ATTIKO Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Transarterial chemoembolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

